Core Insights - Amarin is undergoing a strategic pivot towards a partnered international commercial model and has executed a global restructuring to lower operating expenses, with 2025 being marked as a "substantial achievement" year [2] Group 1: Strategic Partnerships and Restructuring - The exclusive long-term partnership with Recordati, starting in Q3 2025, is a key driver for Amarin's operational review and restructuring initiative [3] - The license and supply agreement with Recordati covers 59 countries, focusing on Europe, and transfers European promotional activities to Recordati [3] - The agreement provides immediate financial value, including a $25 million upfront cash payment and potential future milestone payments up to $150 million, contingent on Recordati achieving $100 million in annual net sales [4] Group 2: Market Performance and Sales Dynamics - Early commercial indicators show growth in volume and demand in launch markets, particularly in Italy, where pricing and reimbursement have been secured [5] - In the U.S., VASCEPA has maintained market leadership among icosapent ethyl products five years post-generic launch, retaining major managed care exclusives through 2025 [6] - U.S. sales for Q4 2025 declined by 7% due to a decrease in net selling price, attributed to proactive pricing strategies [6]

Financial Data and Key Metrics Changes - For the full year 2025, total net revenue was $49.2 million, down from $62.3 million in the previous year’s fourth quarter, reflecting a 21% decline [21] - U.S. sales declined by 7% due to a decrease in net selling price, driven by proactive pricing adjustments [21] - Total operating expenses decreased by 31%, or $13.5 million, with cost of goods sold declining by 63% [23] - The operating loss in the fourth quarter narrowed to $2.3 million from an operating loss of $16 million in the previous year’s fourth quarter [25] - The company ended 2025 with $303 million in cash and investments, no debt, and working capital of $455 million [25] Business Line Data and Key Metrics Changes - Product revenue for Europe was $2.3 million, including $900,000 in supply shipments to Recordati, significantly lower than the $4 million of direct sales in the fourth quarter of 2024 [21][22] - Rest of World revenues were $3.1 million, down from $11.9 million in the previous year’s fourth quarter, impacted by $7.8 million in stocking orders in the last quarter of 2024 [22] Market Data and Key Metrics Changes - VASCEPA maintained clear market leadership in the U.S. across all available icosapent ethyl products, both branded and generic, five years after the introduction of the first generic product [8] - The partnership with Recordati aims to capitalize on the growing awareness of lipid management protocols in Europe, where cardiovascular disease is a leading cause of death [9] Company Strategy and Development Direction - The company established a long-term partnership with Recordati to commercialize VAZKEPA across Europe, aiming to enhance the global market for its franchise [4] - The strategy includes a focus on operational efficiencies and a global restructuring plan expected to yield approximately $70 million in annualized savings by mid-2026 [5][26] - The company is committed to enhancing long-term shareholder value by addressing cardiovascular disease as a leading cause of death [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the VASCEPA franchise and its global growth potential, supported by extensive scientific evidence [7] - The company anticipates 2026 to be a pivotal year, focusing on defending its U.S. franchise and expanding its global presence through the international partnership model [19][25] - Management highlighted the importance of maintaining exclusivity in the U.S. market and expressed confidence in sustaining it through 2026 [38] Other Important Information - The company reported generating positive cash flow from operations of $7 million in 2025, earlier than anticipated [25] - The partnership model will result in revenue variability quarter-to-quarter, influenced by market demand and launch timing [23] Q&A Session Summary Question: Could you provide more color on the volume versus price dynamics in 4Q? - Management noted that volume and price remained consistent compared to Q3, with typical volume declines expected in Q1 [31][32] Question: How confident are you in sustaining exclusivity with your existing exclusive formulary in 2026? - Management expressed confidence in maintaining exclusivity through 2026, despite the dynamic nature of the market [38]

Financial Data and Key Metrics Changes - For the fourth quarter of 2025, total net revenue was $49.2 million, down from $62.3 million in the same quarter of the previous year, reflecting a 21% decline [21] - U.S. sales declined by 7% due to a decrease in net selling price, driven by proactive pricing adjustments [21] - Total operating expenses decreased by 31%, or $13.5 million, with cost of goods sold declining by 63% [24] - The operating loss narrowed to $2.3 million from an operating loss of $16 million in the previous year's fourth quarter [26] - The company ended 2025 with $303 million in cash and investments, no debt, and working capital of $455 million [26] Business Line Data and Key Metrics Changes - Product revenue for Europe was $2.3 million, including $900,000 in supply shipments to Recordati, significantly lower than the $4 million of direct sales in Q4 2024 [22] - Rest of World revenues were $3.1 million, down from $11.9 million in the previous year's fourth quarter, impacted by $7.8 million in stocking orders in Q4 2024 [23] - SG&A expenses declined by 46%, representing 41% of total net sales compared to 59% in the previous year [25] Market Data and Key Metrics Changes - VASCEPA maintained clear market leadership in the U.S. across all available icosapent ethyl products, both branded and generic [7] - The company has established a partnership with Recordati to commercialize VAZKEPA across 59 countries, focusing on Europe, which is expected to enhance market access [9] Company Strategy and Development Direction - The company aims to transform its business model and expand the global market for its VASCEPA/VAZKEPA franchise through strategic partnerships and operational efficiencies [4] - The partnership with Recordati is expected to generate substantial economies of scale and significant revenue opportunities while providing extensive infrastructure [9] - The company is focused on maintaining exclusivity in the U.S. market and expanding its global presence through a partnered international commercial strategy [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the VASCEPA franchise and its global growth potential, supported by a strong body of scientific evidence [6] - The company anticipates a pivotal year in 2026, focusing on defending its U.S. franchise and expanding its global presence [19] - Management highlighted the importance of proven therapies like VASCEPA in the evolving treatment landscape for cardiovascular disease [16] Other Important Information - The company achieved approximately half of the estimated $70 million in total operating expense savings from its global restructuring plan by the end of 2025 [5] - The company expects to incur the last of the restructuring expenses in early 2026 [25] Q&A Session Summary Question: Could you provide more color on the volume versus price dynamics in 4Q? - Management noted that volume and price remained consistent compared to Q3, with typical volume declines expected in Q1 [31][32] Question: How confident are you in sustaining exclusivity with your existing exclusive formulary in 2026? - Management expressed confidence in maintaining exclusivity through the year, citing past successes in regaining exclusives [37]

Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year, primarily due to higher U.S. sales [21] - Net product revenue was $48.6 million, reflecting a $6.7 million or 16% increase [21] - U.S. net product revenue reached $40.9 million, a significant increase of $10.3 million or 34%, driven by a change in customer mix and increased volume [22] - Operating loss for Q3 2025 was $11.1 million, which is $14.1 million or 56% lower than Q3 2024, indicating improved operational efficiency [25] - Operating margin improved to -22% from -60% in the prior year [25] - Cash and investments at the end of the quarter totaled $286.6 million, with no debt and working capital of $446 million [26] Business Line Data and Key Metrics Changes - The transition to a partnered model with Recordati has begun to show results, with product revenue from Europe at $4.1 million, consistent with the prior year [22][23] - Revenue from the rest of the world was $3.6 million, a decline from the prior year, attributed to variability in supply shipments and market demand [23][50] - SG&A expenses were reduced to $19.7 million, a decrease of $17.2 million or 47% compared to the prior year [24] Market Data and Key Metrics Changes - VASCEPA maintained over 50% market share in the IPE market in the U.S., demonstrating resilience five years post-generic entry [11] - The company anticipates that Recordati will fully manage European commercialization by the end of 2025, with sustained momentum in demand across all commercialized European markets [9][10] Company Strategy and Development Direction - The partnership with Recordati marks a strategic shift to a fully partnered commercial model in international markets, aiming to leverage expertise across nearly 100 markets [5][6] - The company is focused on reducing the cardiovascular disease burden globally, with a commitment to operational efficiency and cost savings of $70 million over the next year [8] - The transition to a partnered model is expected to enhance revenue generation and operational efficiency, with a focus on maximizing the clinical impact of VASCEPA [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic actions taken and the potential for growth, particularly in underpenetrated markets [19] - The company is optimistic about achieving positive free cash flow by 2026, supported by a rightsized operating footprint and improved operating margins [26] - The FDA's recent actions regarding fenofibrates are seen as an opportunity to shift clinical practice towards more effective therapies like VASCEPA [14][17] Other Important Information - Restructuring expenses totaled $9.4 million for the quarter, with a total of $32.2 million incurred to date [25] - The company is committed to advancing cardiovascular care through a strong presence at major medical meetings, including the European Society of Cardiology conference [12] Q&A Session Summary Question: U.S. net price trajectory for the back half of 2025 and into 2026 - Management anticipates U.S. net prices to remain consistent for the remainder of 2025, with ongoing negotiations for rebate percentages for 2026 [28][30] Question: Future milestone payments from Recordati - Milestone payments are based on sales performance, triggered as Recordati surpasses $100 million in sales [30] Question: Decline in rest of world revenue - The decline is attributed to variability in supply shipments and the absence of larger launches in the current quarter [48][50]

Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year, primarily due to higher U.S. sales [21] - Net product revenue was $48.6 million, reflecting a 16% increase [21] - U.S. net product revenue reached $40.9 million, a 34% increase driven by a change in customer mix and increased volume [22] - Operating loss for Q3 2025 was $11.1 million, a 56% improvement from the previous year [25] - Cash and investments at the end of the quarter totaled $286.6 million, with no debt [25] Business Line Data and Key Metrics Changes - U.S. business maintained over 50% share of the IPE market, demonstrating resilience five years post-generic entry [11] - European product revenue was $4.1 million, consistent with the prior year, reflecting the transition to a partnered model with Recordati [22][23] - Rest of world product revenue was $3.6 million, a decline from the prior year, attributed to variability in supply shipments [23][51] Market Data and Key Metrics Changes - The transition to a partnered model in Europe is expected to normalize by the end of 2025, with anticipated growth in revenue as operations stabilize [24][42] - The FDA's recent update on phenofibrates may influence prescribing practices globally, potentially benefiting VASCEPA's market position [16][44] Company Strategy and Development Direction - The partnership with Recordati marks a shift to a fully partnered commercial model in international markets, aiming to leverage expertise across nearly 100 markets [5][6] - The company is focused on reducing the cardiovascular disease burden and maximizing the clinical impact of VASCEPA [8][18] - A restructuring initiative aims to achieve $70 million in operational expense savings over the next year [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic actions taken and the potential for growth in both U.S. and international markets [19] - The company anticipates achieving positive free cash flow by 2026, supported by a rightsized operating footprint and improved operating margins [19][26] - The management highlighted the importance of addressing cardiovascular disease through proven outcomes rather than solely improving biomarkers [17] Other Important Information - The company is committed to advancing cardiovascular care through a strong presence at major medical meetings, including the European Society of Cardiology 2025 conference [12] - Restructuring expenses totaled $9.4 million for the quarter, with expectations for lower costs moving forward [25] Q&A Session Summary Question: U.S. net price trajectory for the back half of 2025 and into 2026 - Management anticipates consistency in U.S. net pricing for the remainder of 2025, with ongoing negotiations for 2026 [29][32] Question: Future milestone payments from Recordati - Milestone payments are based on sales performance, triggered as Recordati surpasses $100 million in sales [30][31] Question: Decline in rest of world revenue compared to Q3 2024 - Revenue variability in the rest of the world is due to timing of supply shipments and market demand, with no significant launches in the current quarter [49][51]

Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year period, primarily due to higher U.S. sales [18] - Net product revenue was $48.6 million, reflecting a 16% increase [18] - U.S. net product revenue reached $40.9 million, a 34% increase driven by a change in customer mix and increased volume [19] - Operating loss was $11.1 million, which is $14.1 million or 56% lower than Q3 2024, indicating improved operational efficiency [22] - Q3 2025 operating margin was negative 22%, a significant improvement from negative 60% in the prior year [22] Business Line Data and Key Metrics Changes - The U.S. business maintained over 50% share of the IPE market, demonstrating resilience five years post-generic entry [10] - European product revenue was $4.1 million, consistent with the prior year, reflecting the transition to a partnered model with Recordati [19] - Rest of world product revenue was $3.6 million, a decline from the prior year, attributed to variability in supply shipments [20] Market Data and Key Metrics Changes - The transition to a partnered commercial model with Recordati is progressing well, with expectations for full management of European commercialization by the end of 2025 [8] - The company is focused on expanding patient access in key growth geographies, leveraging partnerships to drive demand [9] Company Strategy and Development Direction - The partnership with Recordati marks a strategic shift to a fully partnered commercial model across international markets, aiming to enhance revenue generation [5] - The company is committed to reducing the cardiovascular disease burden and has implemented a global restructuring to achieve operational efficiency, targeting $70 million in OpEx savings [7] - The focus remains on maximizing the clinical impact of VASCEPA while ensuring financial strength in the U.S. market [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic actions taken and the potential for growth, particularly in underpenetrated markets [17] - The company anticipates achieving positive free cash flow by 2026, supported by a rightsized operating footprint and improved operating margins [22] Other Important Information - The FDA's recent update on phenofibrates is expected to shift clinical practices, potentially benefiting VASCEPA as a preferred therapy for cardiovascular risk reduction [14][15] - The company ended the quarter with $286.6 million in cash and investments, no debt, and working capital of $446 million, indicating a stable capital structure [22] Q&A Session Summary Question: U.S. net price trajectory for the back half of 2025 and into 2026 - Management anticipates consistency in U.S. net prices for the remainder of 2025, with ongoing negotiations for 2026 [25][29] Question: Future milestone payments from Recordati - Milestone payments are based on sales performance, triggered as Recordati surpasses $100 million in sales [27] Question: Gross margin trajectory with a shift towards supply sales to partners - A decline in gross margin percentages is expected as the company moves to a partnered model, but lower operating expenses will benefit operating margins [30] Question: European sales dip due to the transition to Recordati - The transition is expected to normalize by 2026, with anticipated lower restructuring costs moving forward [43] Question: Impact of phenofibrate update on U.S. and Rest of World practices - The FDA's update is expected to influence prescribing practices globally, potentially benefiting VASCEPA as a preferred therapy [46][47] Question: Decline in rest of world revenue compared to Q3 2024 - The decline is attributed to variability in supply shipments and the absence of larger launches in the current quarter [50]

Core Insights - Amarin Corporation has established a partnership with Recordati to enhance the commercialization of VAZKEPA in Europe, which is expected to significantly increase shareholder value [2][4] - The company has initiated a global restructuring plan aimed at achieving $70 million in operating expense savings over the next 12 months [5] - Financial results for Q2 2025 show an 8% increase in total net revenue compared to Q2 2024, primarily driven by licensing and royalty revenue from the European partnership [6][9] Recent Strategic Actions - The exclusive long-term license and supply agreement with Recordati covers 59 countries in Europe, aiming to accelerate VAZKEPA's market adoption [4] - The partnership is expected to facilitate a smooth commercial transition, largely completed by the end of 2025 [4] Global Restructuring - The restructuring is a direct response to the partnership with Recordati, focusing on reducing operating expenses and right-sizing the company's operations [5] - Most of the anticipated savings will come from eliminating commercial roles in European operations [5] Q2 2025 Financial Highlights - Total net revenue for Q2 2025 was $72.7 million, an increase of $5.3 million or 8% from Q2 2024 [6][9] - Operating expenses were $43.6 million, slightly up from $43.3 million in Q2 2024, with a significant restructuring charge of $22.8 million included [6][12] - The company reported a net loss of $14.1 million for Q2 2025, compared to a net income of $1.5 million in Q2 2024 [16] Revenue Breakdown - U.S. product revenue decreased by 17% to $36.5 million, while European revenue increased by 85% to $6.6 million [8] - Licensing and royalty revenue rose by 31% to $26.1 million, primarily due to the upfront payment from the Recordati agreement [9] Cash Position - As of the end of Q2 2025, Amarin reported nearly $300 million in cash and no debt, positioning the company well for future growth [3][16]

Strategic Partnerships & Financial Restructuring - Amarin has entered into an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in 59 countries, primarily in Europe[13] - The Recordati agreement includes $25 million in upfront cash[9] and up to $150 million in milestone payments based on net sales levels[9] - Global restructuring is expected to generate approximately $70 million in cost savings over the next 12 months[6, 16, 24] VAZKEPA/VAZKEPA Market & Growth - VAZKEPA has CVRR indication regulatory approvals in 49 global markets[7] - Demand for VASCEPA/VAZKEPA has grown by 77% in aggregate, comparing Q1 2025 to Q1 2024[22] - The company maintains over 40% share of the IPE market in the U S [21] US Market & Global Expansion - The refined commercial strategy in the U S focuses on payer coverage post-loss of exclusivity[21] - Partnerships in Rest of World are focused on maximizing patient access to VASCEPA globally, with commercialization across 11 countries and regulatory submissions pending in 8 additional markets[23]